Sunshine Biopharma Inc. SEC filings SBFMW
Sunshine Biopharma Inc. has 428 filings in SEC EDGAR's recent list, going back to May 25, 2007. Its latest annual report, Form 10-K, was filed on Apr 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14C | Information statement | Oct 27, 2026 | Oct 30, 2026 |
| PRE 14C | Preliminary information statement | Oct 14, 2026 | Oct 14, 2026 |
| DEF 14C | Information statement | Sep 28, 2026 | Sep 15, 2026 |
| PRE 14C | Preliminary proxy | Sep 16, 2026 | Sep 15, 2026 |
| DEF 14C | Information statement | Jun 8, 2026 | Jun 8, 2026 |
| PRE 14C | Preliminary information statement | May 29, 2026 | May 29, 2026 |
| DEF 14C | Information statement | Mar 2, 2026 | Mar 2, 2026 |
| PRE 14C | Preliminary information statement | Feb 20, 2026 | Feb 18, 2026 |
| DEFA14A | Additional proxy material | Oct 23, 2025 | — |
| DEF 14A | Proxy statement | Oct 23, 2025 | Dec 11, 2025 |
| DEF 14A | Proxy statement | Oct 17, 2024 | Dec 10, 2024 |
| DEF 14C | Information statement | Jul 11, 2024 | Jun 28, 2024 |
| PRE 14C | Form pre 14c | Jul 1, 2024 | Jul 1, 2024 |
| DEF 14C | Information statement | Mar 15, 2024 | Mar 20, 2024 |
| PRE 14C | Preliminary information statement | Mar 5, 2024 | Mar 5, 2024 |
| DEF 14C | Information statement | Mar 5, 2024 | Mar 8, 2024 |
| PRE 14C | Filing | Feb 21, 2024 | Feb 21, 2024 |
| DEFA14A | Additional proxy material | Oct 19, 2023 | — |
| DEF 14A | Proxy statement | Oct 18, 2023 | Dec 7, 2023 |
| DEF 14A | Proxy statement | Sep 5, 2023 | Oct 12, 2023 |
| PRE 14A | Preliminary proxy statement | Aug 25, 2023 | Oct 12, 2023 |
| PRE 14A | Preliminary proxy statement | May 2, 2023 | May 31, 2023 |
| DEF 14C | Information statement | Jan 18, 2022 | Jan 20, 2022 |
| PRE 14C | Filing | Jan 6, 2022 | Jan 15, 2022 |
| DEF 14C | Information statement | Oct 6, 2021 | Sep 8, 2021 |
| PRE 14C | Filing | Sep 21, 2021 | Oct 31, 2021 |
| DEF 14C | Information statement | Mar 24, 2020 | Mar 24, 2020 |
| PRE 14C | Preliminary information statement | Jan 6, 2020 | Jan 3, 2020 |
| DEF 14C | Information statement | Jan 31, 2019 | Feb 1, 2019 |
| PRE 14C | Information statement | Nov 28, 2018 | Nov 28, 2018 |
| DEF 14C | Information statement | Jun 13, 2016 | Jun 15, 2016 |
| PRE 14C | Preliminary information statement | Jun 1, 2016 | Mar 30, 2016 |
| DEF 14C | Information statement | Jun 23, 2015 | Jun 25, 2015 |
| PRE 14C | Preliminary proxy statement | Jun 8, 2015 | Jun 8, 2015 |
| PRE 14C | Schedule 14c | Sep 16, 2013 | Sep 13, 2013 |
| DEF 14C | Information statement | May 4, 2010 | May 4, 2010 |
| PRE 14C | Preliminary schedule 14c | Apr 21, 2010 | Apr 20, 2010 |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SBFM (Nasdaq), SBFMW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CO
- Headquarters
- Fort Lauderdale, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1402328
- Former names
- Sunshine Biopharma, Inc (until Oct 17, 2024); Mountain West Business Solutions, Inc (until Nov 2, 2009); mountain west business solutions,inc (until Oct 19, 2007); mountain state business solutions,inc (until May 25, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.